Document Detail

Efficacy of intravenous immunoglobulin treatment in refractory uveitis.
MedLine Citation:
PMID:  17162608     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To assess the efficacy of intravenous immunoglobulin (IVIg) therapy in patients with severe uveitis otherwise unresponsive to conventional immunomodulatory agents. METHODS: Data on five consecutive patients treated with IVIg and followed to the present time by one of the authors (CSF) were reviewed. All patients had severe and recalcitrant uveitis of diverse etiologies. Main outcome measures were control of intraocular inflammation, steroid-sparing effect, visual acuity, and side effects. RESULTS: The duration of IVIg therapy was 3 to 36 months (mean, 16.8 months). Treatment was effective in controlling the intraocular inflammation in 3 of 5 patients. One of those patients required maintenance of systemic steroids at a dose of 10 mg per day. Visual acuity has stabilized or improved in these three patients. No immediate or long-term side effect was observed in any of the patients. CONCLUSIONS: Intravenous immunoglobulin therapy was an effective therapeutic modality in the treatment of three of five patients with severe uveitis that was unresponsive to conventional immunomodulatory agent(s). No adverse events were observed.
Sumru Onal; C Stephen Foster; A Razzaque Ahmed
Related Documents :
8774518 - Failure of pulse intravenous methylprednisolone treatment in juvenile dermatomyositis.
17943798 - Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for ...
22165838 - Case series of selenium toxicity from a nutritional supplement.
20038218 - Experience with everolimus (rad001), an oral mammalian target of rapamycin inhibitor, i...
21494878 - Early visual impacts of optical coherence tomographic parameters in patients with age-r...
12615868 - Optimizing ceftazidime pharmacodynamics in patients with acute exacerbation of severe c...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Ocular immunology and inflammation     Volume:  14     ISSN:  0927-3948     ISO Abbreviation:  Ocul. Immunol. Inflamm.     Publication Date:  2006 Dec 
Date Detail:
Created Date:  2006-12-12     Completed Date:  2007-02-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9312169     Medline TA:  Ocul Immunol Inflamm     Country:  England    
Other Details:
Languages:  eng     Pagination:  367-74     Citation Subset:  IM    
School of Medicine, Department of Ophthalmology, Marmara University, Istanbul, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Drug Resistance
Follow-Up Studies
Glucocorticoids / therapeutic use
Immunoglobulins, Intravenous / therapeutic use*
Immunologic Factors / therapeutic use*
Uveitis, Anterior / drug therapy*,  pathology
Visual Acuity
Reg. No./Substance:
0/Glucocorticoids; 0/Immunoglobulins, Intravenous; 0/Immunologic Factors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The expression of nuclear factor kappa B in inflammation-induced rat corneal neovascularization.
Next Document:  Intravitreal triamcinolone acetonide treatment for serpiginous choroiditis.